Science_TechnologyHealth
News 14 of 23

SHetA2 Oral Therapy Blocks HPV Cancer Proteins; ICMR-Emcure Phase II Trials Underway

Science & TechSocial IssuesCORE
Target:UPSC GS-IIIMPSCSSC GATeachingPrelims HighMains MediumStatic GK Link
27 Jul 2026
~2 min
Source: Indian Express
Key Data:79,000 cases36,319 deaths85% of cervical cancers caused by HPVSHetA2mortalinhsc70
Bodies:ICMR-NICPREmcure PharmaceuticalsStephenson Cancer Center, University of Oklahoma
Practice MCQs from today's news ▸
What This Article Covers

1.SHetA2 is a small-molecule oral therapy that targets host proteins (mortalin, hsc70, Grp78) to break the HPV-E7 connection, allowing the body to destroy the harmful E7 protein.

2.Cervical cancer is the second most common cancer among women in India, with 79,000 cases and 36,319 deaths in 2024 (Global Cancer Observatory data).

3.ICMR-NICPR validated the mechanism; the drug is now with Emcure Pharmaceuticals for larger human trials that may take up to 5 years.

The Big Picture
Prelims · HighMains · Medium

A novel oral therapy, SHetA2, has shown promise in blocking HPV from turning precancerous lesions into cervical cancer. Developed by University of Oklahoma and validated by ICMR-NICPR, the drug has been transferred to Emcure Pharmaceuticals for Phase II trials. This is a major step in cervical cancer prevention, especially for India where it is the second most common cancer among women, killing over 36,000 annually.

Exam Lens

Quick Exam Facts From News

Cancer typeCervical cancer (second most common among women in India)
HPV linkage85% of cervical cancers caused by persistent HPV infection
India cases (2024)79,000 cases; 36,319 deaths
Drug nameSHetA2 (oral capsule)
Key partnerEmcure Pharmaceuticals (for Phase II trials)
Target proteinsmortalin, hsc70, Grp78

1-Minute Revision

  • ›Cancer type: Cervical cancer (second most common among women in India)
  • ›HPV linkage: 85% of cervical cancers caused by persistent HPV infection
  • ›Target this Data: 79,000 cases, 36,319 deaths in India (2024); 85% of cervical cancers linked to HPV
  • ›Target this Drug: SHetA2 (oral capsule) targeting host proteins mortalin, hsc70, Grp78
  • ›Target this Nodal Body: ICMR-National Institute of Cancer Prevention and Research (ICMR-NICPR); Emcure Pharmaceuticals for Phase II trials

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

Q1Static LinkageEasy

Which Indian institute validated the mechanism of action of SHetA2 therapy for cervical cancer?

Q2Statement-basedHard

Consider the following statements regarding SHetA2 therapy:

1. It is an oral capsule that can prevent HPV infection.

2. It works by breaking the connection between the HPV-E7 protein and a host protein, allowing the immune system to destroy E7.

3. It is expected to be more affordable than biologic or immunotherapy-based cancer treatments.

Which of the statements given above is/are correct?

Q3Data-centricMedium

According to Global Cancer Observatory data (2024), how many women in India died from cervical cancer?

Q4Application/ImpactMedium

What is the primary objective of the SHetA2 therapy as described in the news?

All 25 MCQs ▸
Read original article from Indian Express
You finished this topic
Practice 3 MCQs from this newsNext Article
Explore Related Topics
Science & TechView Topic MCQs →Social IssuesView Topic MCQs →
PreviousCWRC Orders Karnataka to Release 3,500 Cusecs/Day to Tamil Nadu Amid 35% Rainfall DeficitNext Public Examinations (Prevention of Unfair Means) Amendment Bill 2026: Harsher Penalties, 60-Day Probe, 3-Month Trial
Related Current Affairs
Science & Tech Current Affairs

Merck-Moderna mRNA Drug Intismeran Autogene Cuts Melanoma Recurrence in Phase 3 Trial with 1,137 Patients

For the first time, an mRNA-based personalized cancer vaccine (intismeran autogene) developed by Merck and Moderna has proven effective in reducing melanoma recurrence in a large late-stage trial with 1,137 patients. This marks a breakthrough in cancer immunotherapy, demonstrating that mRNA technology, previously successful against COVID-19, can be adapted to fight cancer.

Science & Tech Current Affairs

Merck-Moderna's Personalised mRNA Cancer Vaccine Intismeran Reduces Melanoma Death Risk by 49%

A first-of-its-kind personalised mRNA cancer vaccine (intismeran), developed by Merck and Moderna, combined with Keytruda, has shown a 49% reduction in risk of death from melanoma recurrence and 59% from spread in Phase 3 trials. This marks a breakthrough for cancer vaccines but has limited impact in India due to low melanoma incidence and high cost of immunotherapy.

Polity Current Affairs

MeitY Summons Meta Global Team Over Algorithmic Bias; Parliamentary Panel to Question

Government summons Meta's global team to clarify algorithmic bias and role in public order after MeitY rejects technical glitch explanation. Parliamentary panel will also question the company. This highlights growing regulatory scrutiny on social media algorithms and their societal impact.

Science & Tech Current Affairs

India Gets First Disease-Modifying Alzheimer's Drug Leqembi After CDSCO Nod

Eisai's Leqembi (lecanemab), India's first disease-modifying therapy for early Alzheimer's, has been launched after CDSCO approval. This marks a shift from symptomatic to disease-modifying treatment, but challenges of early diagnosis, biomarker infrastructure, and affordability remain significant.

Social Issues Current Affairs

NOTTO Reports 20,000+ Transplants in 2025, Launches Portal and Swap Guidelines

NOTTO released 2025 data showing over 20,000 transplants, persistent gender disparity in organ donation (68% female donors vs 78% male recipients), and launched a new digital portal to enhance transparency. New swap transplantation guidelines aim to expand matching beyond single hospitals, but legal recognition under THOTA is still pending.

Science & Tech Current Affairs

IARC Classifies Three WHO Essential Medicines as Group 1 Carcinogens: Hydrochlorothiazide, Voriconazole, Tacrolimus

IARC, the WHO cancer research agency, has classified three widely used drugs—hydrochlorothiazide, voriconazole, and tacrolimus—as Group 1 carcinogens. Despite this, experts stress that patients should not stop treatment as the benefits for hypertension, fungal infections, and organ transplant rejection far outweigh the cancer risk. The drugs are on the WHO Model List of Essential Medicines and are commonly prescribed in India.

Science & Tech Current Affairs

IISc SraVaani: India's First Open-Source Speech Recognition Model for 65 Languages

IISc's SPIRE Lab, in collaboration with ARTPARK and Google, has released SraVaani – the first multilingual Indian speech recognition model trained on 65 languages and dialects. It extends ASR to 45 underserved regional languages, potentially benefiting 25 crore people. This marks a major step in inclusive AI for India's linguistic diversity.

Social Issues Current Affairs

Meta Trial: $567 Mn Penalty for Child Addiction, 29-State Probe on Social Media Design

A US trial against Meta over addictive social media design for children could reshape Big Tech accountability. With penalties of $567 million and a $6 million jury verdict, this case highlights the growing scrutiny of platform design and its impact on youth mental health, a key issue for GS2 (Social Justice) and GS3 (Technology).

Start Today's Quiz(25 Qs)